Pleased to Support the Cancer Screening Research Network Vanguard Study – NCI Division of Cancer Prevention
NCI Division of Cancer Prevention shared a post on LinkedIn by Fred Hutch, adding:
“NCI is pleased to support the Cancer Screening Research Network (CSRN) Vanguard Study. This pilot study is an important step towards understanding how multi-cancer detection (MCD) tests perform in real-world settings.”
Quoting Fred Hutch‘s post:
“Fred Hutch Cancer Center is leading the newly launched Vanguard Study, a national study of a new type of blood test that screens for several different cancers called multi-cancer detection (MCD) tests. Researchers will evaluate whether these blood tests will help people ages 45 to 75 find cancer early when it may be easier to treat.
This is the first study of the Cancer Screening Research Network (CSRN), a nationwide network that will run trials aimed at improving cancer screening that is funded by the National Cancer Institute (NCI), part of the National Institutes of Health. Fred Hutch serves as the Coordinating and Communications Center as well as the Statistics and Data Management Center.”
More posts featuring NCI Division of Cancer Prevention.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023